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A B S T R A C T   
Full thickness models (FTM) are 3D in vitro skin cultures that resemble the native human skin (NHS) to a great 
extent. However, the barrier function of these skin models is reduced. The skin barrier is located in the stratum 
corneum (SC) and consists of corneocytes embedded in a lipid matrix. In this matrix, deviations in the compo-
sition of the FTMs lipid matrix may contribute to the impaired skin barrier when compared to NHS. One of the 
most abundant changes in lipid composition is an increase in monounsaturated lipids for which stearoyl-CoA 
desaturase-1 (SCD-1) is responsible. To improve the SC lipid composition, we reduced SCD-1 activity during 
the generation of the FTMs. These FTMs were subsequently assessed on all major aspects, including epidermal 
homeostasis, lipid composition, lipid organization, and barrier functionality. We demonstrate that SCD-1 inhi-
bition was successful and resulted in FTMs that better mimic the lipid composition of FTMs to NHS by a sig-
nificant reduction in monounsaturated lipids. In conclusion, this study demonstrates an effective approach to 
normalize SC monounsaturated lipid concentration and may be a valuable tool in further optimizing the FTMs in 
future studies.   
1. Introduction 
Full thickness skin models (FTMs) are in vitro skin models that mimic 
native human skin (NHS) in many aspects and serve as a valuable tool to 
unravel biological processes in healthy and diseased skin [1]. In addi-
tion, FTMs serve as an excellent tool for the prediction of toxicity 
screenings and diffusion of novel compounds as an alternative for ani-
mal experiments [1–4]. However, the most important drawback is the 
reduced barrier function of the FTMs [5–8]. This limits the use of FTMs 
in the prediction of novel pharmaceutical compounds on their diffusion 
across the skin. Therefore, there is an urgent need for a new generation 
of FTMs that mimic the NHS barrier properties more closely. To improve 
the skin barrier of the FTMs, normalization of the stratum corneum (SC) 
lipid composition is considered to be crucial [9–11]. 
The outside-in NHS barrier is primarily located in the SC, which 
consists of corneocytes embedded in a lipid matrix [12]. In this lipid 
matrix, three main lipid classes are present: cholesterol, free fatty acids 
(FFAs), and ceramides (CERs). The CERs are the most complex of these 
lipids and over 16 subclasses have been identified [13–15]. In addition 
to different subclasses, each subclass has a broad distribution in their 
total chain length as well (sphingoid base + acyl chain) [16,17]. 
Although less variety in subclasses, the FFAs also have a broad distri-
bution of chain length. Together with cholesterol, these lipids can 
organize themselves into two lamellar phases, the short periodicity 
phase (SPP) with a repeat distance of around 6 nm and the long peri-
odicity phase (LPP) with a repeat distance of approximately 13 nm 
[18,19]. Within the lamellae, the lipids can adopt a very dense (ortho-
rhombic), a less dense (hexagonal) packing or even a fluid phase. The 
lipid organization is depicted schematically in Fig. S1 and the molecular 
structure of the various CER subclasses are described in Fig. S2. 
Differences in lipid composition and organization have been re-
ported between the FTMs and NHS [16,20]. One of the most prevalent 
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differences is a high level of monounsaturated CERs (muCERs) and 
monounsaturated FFAs (muFFAs). Besides this major difference, other 
differences are observed as well: 1) an altered CER subclass profile, 2) a 
strong reduction in the FFA amount, 3) a reduction in the mean chain 
length (MCL) of the CERs and FFAs [5,16,21]. These changes in lipid 
composition lead to changes in the lipid organization. The most pre-
dominant ones include a shorter repeat distance of the LPP, the absence 
of the SPP and a less dense lipid packing: lipids adopt mainly a less dense 
hexagonal packing. Ultimately, these changes contribute to a reduced 
barrier function in the FTMs [16,20]. 
The aim in this study was to improve the lipid composition by 
reducing the level of muCERs and muFFAs in our in-house FTM model. 
This in-house model displays the alteration in lipid composition and 
organization as described above, such as an increase in monounsatura-
tion of the lipids [16]. A possible underlying factor for this is the enzyme 
stearoyl-CoA desaturase-1 (SCD-1). Studies have reported that this 
enzyme is overexpressed and is also present in the suprabasal layers, 
whereas in NHS, SCD-1 is mainly expressed in the basal layer [16,21]. 
SCD-1 serves as a catalyst for creating a double bond at the Δ9 car-
bon in saturated FFAs (C16:0 and C18:0) to convert them in their 
monounsaturated counterparts (C16:1, and C18:1), respectively [22]. 
Subsequently, these saturated FFAs (saFFAs) and muFFAs are elongated 
by a group of elongases referred to as ELOVLs and finally incorporated 
into the SC lipid matrix [23]. Next, these (mu)FFAs are also building 
blocks for CERs and are linked to a sphingoid base by the group of 
ceramide synthases leading to the more complex CER subclasses 
[24–26]. However, this means that a higher quantity of both CERs and 
FFAs that contain monounsaturated bonds in their acyl chains are syn-
thesized. These muCERs and muFFAs are key factors that contributes to 
the formation of a less dense hexagonal organization [9]. To reduce the 
level of monounsaturation in the SC lipids, the culture medium of our in- 
house developed FTM was supplemented with an SCD-1 inhibitor to 
normalize the lipid monounsaturation. 
After generation of FTMs, the lipid composition was analyzed and a 
drastic reduction in the amount of muCERs and muFFAs were observed. 
This demonstrates that the SCD-1 inhibitor successfully inhibited the 
SCD-1 activity. In addition, changes were observed in the lipid synthesis, 
such as the increase in CER[dS] and the overall reduction in CER(EO) 
subclasses. 
2. Materials and methods 
Methods performed in this study are briefly described below. A more 
detailed description can be found in the Supplemental materials and 
methods (Supp. Methods). 
2.1. Generation of the full thickness models 
Prior to the SCD-1 study, two concentrations of SCD-1 inhibitor were 
tested: 45 nM and 450 nM. However, the 450 nM did not result in viable 
FTMs, therefore this study was performed with 45 nM as concentration 
for the SCD-1 inhibitor. To study the effects of SCD-1 inhibition, all 
studies were performed in triplicate using keratinocytes from three fe-
male donors (3 Caucasian female skin donors aged between 18 and 26, 
cell isolation is described in Supp. Methods 1). Two out of three origi-
nating NHS keratinocyte donor samples were also used as a control in 
the following subsequent studies (liquid-chromatography-mass spec-
trometry (LC-MS), quantitative polymerase chain reaction (qPCR), small 
angle X-ray diffraction (SAXD)). Due to limit of sample material the 
third control was from an additional donor. Using each donor, the FTMs 
were generated in triplicate. First, the dermal compartment was pre-
pared as reported in detail previously [5,27]. To this end, rattail- 
collagen was populated with fibroblasts (4 × 104 fibroblasts/ml) as 
described before [5]. After 7 days of culturing the dermal compartment, 
keratinocytes (2.5 × 105 cells) were seeded onto each dermal 
compartment and subsequently cultured for another four days under 
submerged conditions. Then the FTMs were lifted to the air-liquid 
interface and the SCD-1 inhibitor was supplemented to the culture me-
dium. The FTM conditions were: 1) FTMCONTROL, that contained normal 
culture medium as described elsewhere [20], 2) FTMSCD-1 that contained 
in addition to the normal culture medium, 45 nM of SCD-1 inhibitor 
AB142089 (Sigma-Aldrich, Zwijndrecht, the Netherlands) dissolved in 
0.05% DMSO of the culture medium (v/v), 3) FTMDMSO supplemented 
with 0.05% DMSO in the medium was cultured to serve as a second 
control. The results obtained in this study for FTMDMSO and the 
FTMCONTROL were similar in all features, therefore, the FTMDMSO are not 
shown in the Results section. The FTMs were cultured air exposed for a 
period of 14–17 days and medium was refreshed twice a week with 
freshly prepared supplements [27,28]. Subsequently, the SC was 
removed from the viable epidermis by trypsin digestion and used for 
analysis (Supp. Methods 1.1). 
2.2. Analysis of the FTMs 
To examine the effects of the SCD-1 inhibitor on the various char-
acteristics of the FTMs, the following analyses were performed: immu-
nohistochemistry (Supp. Methods 1.2), LC-MS (in Supp. Methods 1.3), 
qPCR (Supp. Methods 1.4), SAXD (in Supp. Methods 1.5), Fourier 
transformed infrared spectroscopy (FTIR, in Supp. Methods 1.6), and 
trans epidermal water loss (TEWL, in Supp. Methods 1.7). 
2.3. Statistical analysis 
Statistical analysis was performed in Graphpad 7. For statistical 
analysis, an unpaired t-test was performed between the FTMCONTROL and 
FTMSCD-1. To compare the FTMCONTROL against NHS, an unpaired t-test 
was used. Significant differences are indicated by * for p < 0.05, ** for p 
< 0.01, and *** for p < 0.001. 
3. Results 
3.1. Supplementation of the SCD-1 inhibitor led to minor changes in the 
epidermal homeostasis but drastically increased SCD-1 protein expression 
Before the initial study on FTMs, a small pilot was performed to 
determine the effects of the SCD-1 inhibitor in two different concen-
trations; 45 nM and 450 nM. The concentration of 45 nM is based on the 
reported IC50 of AB142089, which was 4.5 nM [21]. In addition to an 10 
times increase, that would already demonstrate an effect without 
causing toxicity to the FTMs, we also wanted to include a higher con-
centration of the inhibitor (450 nM). This was initiated due to the high 
percentage of monounsaturation in the lipids of FTMs and to determine 
whether it would be more beneficial. However, the inhibitor concen-
tration of 450 nM did not lead to a viable FTM (Fig. S2). Therefore, the 
study was performed with inhibitor SCD-1 concentration of 45 nM 
(referred to as the FTMSCD-1), which was supplemented to the culture 
medium. 
After culturing, FTMs and NHS were investigated on basal cell pro-
liferation, early, and late differentiation by several epidermal homeo-
stasis proteins markers (Fig. 1). Basal cell proliferation was examined by 
a Ki67 protein staining. As shown in Fig. 1, no significant changes in 
Ki67 expression was observed, irrespective the condition tested. Next, 
the early differentiation was investigated by staining for keratin 10 
(K10) (Fig. 1). K10, which stains the suprabasal cell layers, showed no 
changes in expression, indicating a normal execution of the early dif-
ferentiation program. Next the late differentiation protein involucrin 
was stained. This protein was similarly expressed in FTMCONTROL and 
FTMSCD-1 and equally present in the stratum granulosum as well as the 
stratum spinosum, whereas in NHS, involucrin was restricted to the 
stratum granulosum (Fig. 1). When examining the SCD-1 expression, a 
significant difference was observed: The FTMSCD-1 displayed a drastic 
increase in SCD-1 expression compared to FTMCONTROL, but both 
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displayed expression throughout the epidermis. In NHS, SCD-1 expres-
sion was less prominently present and more restricted to the basal layer 
(Fig. 1). 
3.2. SCD-1 inhibition led to reduction of monounsaturated CER 
subclasses 
To determine whether SCD-1 inhibition led to changes in the SC lipid 
composition, the CER profile in FTMs and NHS was examined. First, the 
extracted amount of SC lipids was determined (Fig. 2a). The amount of 
extracted lipids was similar between FTMs, but was significantly 
increased in NHS compared to the FTMs. After the lipid extraction, the 
peaks of all CER subclasses (saCER+muCER) in the LC-MS spectrum 
were integrated, processed and converted to CER amounts in nmol/mg 
SC (Fig. 2b). No differences in the total amount of CERs in nmol/mg SC 
between the FTMs and NHS were observed. Next, the absolute amounts 
of the CER subclasses were analyzed. 
3.2.1. Quantified CER subclass composition 
The individual subclasses of CER[non-EO], CER[EO], and CER[O] 
were plotted in absolute amounts (Fig. 2c, e, f, respectively). Individual 
analysis of the quantified subclasses of CER[non-EO] revealed a similar 
subclass profile after SCD-1 inhibition compared to FTMCONTROL, except 
for an increased amount of CER[dS] subclass in FTMSCD-1. Compared to 
NHS, in both FTMCONTROL and FTMSCD-1 an altered amount of CER [NS], 
[AS], [NH], [NP] and [NH] subclasses was observed. More drastic 
Fig. 1. Different epidermal homeostasis markers and SCD-1 were examined in FTMs and NHS. Expression of protein markers in FTMCONTROL, FTMSCD-1 and NHS from 
left to right: negative control, proliferation (Ki67), early differentiation (K10), late differentiation (involucrin), and lipid monounsaturation enzyme SCD-1. Ki67 
proliferation index determination. Scale bar: 50 μm. 
Fig. 2. SCD-1 inhibition alters lipid composition by reducing the monounsaturation, reducing the CER[EO] subclasses, and by increasing the CER[dS] fraction. 
During sample preparation, (a) the amount of extracted lipids was determined. (b) The total amount of CERs (saCER+muCER) in nmol/mg SC. (c) The subclasses of 
the CER[non-EO] (saCER+muCER). (d) The total amount of muCER[non-EO] (muCERs in nmol/mg SC). (e) Subclasses in CER[EO] (saCER+muCER). (f) Subclasses 
in CER[O] (saCER+muCER). The mean chain lengths for (g) saCER[non-EO] and (h) CER[EO] main peak (saCER[EO-18:2] + muCER[EO-18:1]. For statistical 
analysis, an unpaired t-test was performed between the FTMCONTROL and FTMSCD-1. After, to compare the FTMCONTROL and NHS, an unpaired t-test was used. Sig-
nificant differences are indicated by * for p < 0.05, ** for p < 0.01, and *** for p < 0.001. 
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changes were observed when examining the amount of muCERs after 
SCD-1 inhibition (Fig. 2d). This demonstrated that the SCD-1 inhibitor 
successfully reduced the amount of muCERs to a level more closely to 
that in NHS. 
In addition to the CER[non-EO], the CER[EO] subclasses were also 
quantified (Fig. 2e). The total amount of CER[EO] was reduced in 
FTMSCD-1, this was mainly caused by the reduction in CER[EOS] (p =
0.07) and a significant reduction in CER[EOP] and CER[EOH] sub-
classes. To study the underlying factor of this reduction, the individual 
monounsaturated and saturated subclasses of CER[EO] with either oleic 
(C18:1) or linoleic (C18:2) acid chain were analyzed (Fig. S4). This 
displayed that it was not one individual CER[EO] subset that was 
reduced, but all subsets were reduced. This reduction was most preva-
lent in the CER[EOS], where the combined amount of muCER[EO- 
18:1]/ saCER[EO-18:2] was decreased (Fig. S4a, p = 0.06). Similar re-
sults were observed for the muCER[EO-18:2] (Fig. S4b, p = 0.11) and 
saCER[EO-18:1] (Fig. S4c, p = 0.07). 
Next, to determine whether the decrease in amount of CER[EO] was 
due to a change in the CER[O] content as these have a common synthetic 
pathway, the amount of CER[O] (saCER+muCER) was determined 
(Fig. 2f). The amount of CER[O] was similar between the FTM condi-
tions tested. However, when studying the saCER[O] and muCER[O] 
composition separately (Fig. S5), an increase (but not significant) in 
subclasses of saCER[O] in the FTMSCD-1 was observed more comparable 
to NHS, although NHS still has significantly higher amount of saCER[O]. 
Another important aspect for the barrier is the mean chain length 
(MCL) of the lipids. This was determined for both saCER[non-EO] 
(Fig. 2g) and the main CER[EO] subclass (Fig. 2h) subclasses. Inhibi-
tion of SCD-1 did not have an impact on the MCL of the CER[non-EO]; 
The MCL was still shorter compared to that of NHS [21,29]. The MCL 
of CER[EO] were comparable between the FTMs and NHS groups and 
did not change in the FTMSCD-1 compared to FTM. In addition, to 
determine whether some CER chain lengths were more abundantly 
present in FTMSCD-1 than in FTM, the chain length distribution was 
determined in absolute and relative amounts (Fig. S6). The absolute 
chain length distribution displayed some minor but significant differ-
ences between the FTM conditions for CER[non-EO] subclasses. The 
amount of CERs with a chain length of C36, C38, C44 and C46 were 
increased in FTMSCD-1 compared to FTMCONTROL. When comparing the 
CER chain length profile of the FTMs to NHS, there is still a large amount 
of CER of <C42 present in FTMs, where in NHS most CERs contain 
>C42. Next, the absolute CER[EO] chain length distribution was 
investigated. For most of the chain lengths (with the exception of C68, 
and C74) the chain length distribution of CER[EO] in FTMSCD-1 
mimicked closely the distribution in NHS. However, this was mainly due 
to the decreased total amount of CER[EO] in FTMSCD-1. When examining 
the relative chain length distribution, hardly no difference in chain 
length distribution was present between FTMSCD-1 and FTMCONTROL. 
3.2.2. Relative CER subclass composition 
In order to relate changes in lipid composition to lipid organization, 
relative amounts of CER subclasses are important. The composition of 
the relative amounts of CER[non-EO] and CER[EO] are reported in 
Figs. S7 and S8, respectively. Briefly, the CER changes reported in Fig. 2 
became more prominent when determining the percentage of CER 
subclasses. Such as the higher percentage of CER[dS] subclass and a 
significant reduction of most of the CER[EO] subclasses: CER[EOS], 
[EOH], and [EOP]. Finally, when examining the level of CER[non-EO] 
monounsaturation, the difference was more abundant (p = 0.007 vs p 
= 0.05) when the amount of CERs (%) was calculated for each FTM 
donor. 
3.3. SCD-1 inhibition reduced muFFA in FTMs 
3.3.1. Quantified FFA analysis 
The total amount of FFA in FTMs (saFFA+muFFA) did not change 
upon SCD-1 inhibition (Fig. 3a). Inhibition of SCD-1 did not change the 
chain length distribution of saFFA either (Fig. 3b). The amount of all 
saFFA irrespective of their chain length was strongly reduced compared 
to NHS as observed in earlier studies [21,29]. Next, the muFFA profile 
was determined (Fig. 3c). Inhibition of SCD-1 reduced the amount of 
muFFA C16:1, C18:1, and C24:1 in the FTMSCD-1 compared to 
FTMCONTROL. This was also reflected in the total amount of muFFA 
(Fig. 3d) and resulted in a reduced percentage of muFFA in FTMSCD-1, as 
shown in Fig. 3e. This percentage indicates that the muFFA content in 
FTMs were higher than in NHS and SCD-1 inhibition was a valuable 
approach to reduce the muFFA content to mimic more closely the level 
in NHS. In addition, the FFA MCL was determined (Fig. 3f), SCD-1 in-
hibition did not affect the MCL. 
3.3.2. Relative FFA analysis 
In order to relate changes in FFA composition to lipid organization, 
percentages of FFA subclasses were also calculated (Fig. S9). These re-
sults demonstrate that especially long chain FFAs (>C24) were reduced 
and the short chain FFAs (<C22) were increased in FTMs compared to 
NHS. Although no significant effects were observed by SCD-1 inhibition 
on the MCL of the lipids, the muFFA content was significantly reduced in 
the FTMSCD-1. 
3.4. Effect of the SCD-1 inhibition on the lipid synthesis genes 
To obtain information on the underlying factors that might explain 
the lipid composition changes after SCD-1 inhibition, several genes that 
are involved in lipid synthesis, elongation of FFA, and the CER synthesis 
were investigated (Fig. 4). 
For the lipid processing genes (SREBP-1c, ACC, and FAS), no differ-
ence in gene expression between the FTMSCD-1 and FTMCONTROL was 
observed. This was also observed for the lipid elongation genes ELOVL-1 
and ELOVL-4 (Fig. 4b). However, an increased ELOVL-4 expression was 
observed in FTMs when compared to NHS. The next gene that was 
investigated was SCD-1 (Fig. 4c). This gene was drastically increased in 
the FTMSCD-1 when compared to the FTMCONTROL. FTMCONTROL already 
expressed significantly higher SCD-1 compared to NHS. To examine 
whether this increase was driven by LXR activation, ABCA1 gene 
expression (Fig. 4c) was investigated. However, no change in this gene 
was observed, excluding LXR activation as underlying factor. Next, the 
CER synthesis genes were investigated. No differences in expression of 
the Ceramide Synthases (CerS) were observed between FTMs (Fig. 4d). 
However, a higher expression for CerS2 and CerS3 were observed in 
FTMs compared to NHS. Finally, the gene expression of the enzymes that 
play a role in the head group synthesis were examined. DES1 and DES2 
convert the CER[dS] subclass to CER[S] and CER[P], respectively. No 
differences were observed for these genes in FTMCONTROL and FTMSCD-1. 
However, DES2 was slightly decreased in FTMs compared to NHS. 
3.5. Effect of SCD-1 inhibition on the lipid organization and TEWL 
To investigate whether the changes in lipid composition affected 
lipid organization and subsequently SC barrier, the lipid organization 
and SC barrier function were examined (Fig. 5). For comparison all 
presented data were measured at 24 ◦C. 
FTIR was used to determine the lateral organization of the lipids 
(Fig. 5a). We present the rocking vibrations at 24 ◦C, the temperature at 
which the TEWL measurement was performed (see below). The high 
peak intensity of the vibration located at 719 cm− 1 together with a small 
shoulder located at 730 cm− 1 in the FTIR spectrum of FTMCONTROL in-
dicates that most lipids adopt a hexagonal packing. A similar rocking 
pattern was observed for FTMSCD-1. In the spectrum of NHS, the intensity 
of the vibrations at 730 cm− 1 was much stronger indicating that a higher 
fraction of lipids adopt to an orthorhombic organization. This demon-
strates a less dense lipid organization in the FTMs compared to that in 
NHS. 
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Next, we determined the lamellar organization using X-ray diffrac-
tion (Fig. 5), the peak positions, indicated by I, II and III refer to the 
various orders of a lamellar phase with a repeat distance of 12.1 nm and 
12.2 nm for the FTMSCD-1 and FTMCONTROL, respectively. Besides this 
diffraction pattern two additional small peaks were observed in the 
SAXD profile, indicated by + and #. 
To determine whether the changes in lipid organization (FTIR and 
SAXD) led to a change in the barrier function of FTMSCD-1 compared to 
FTMCONTROL the TEWL was measured for FTMs and NHS (Fig. 5c). No 
differences were observed after SCD-1 inhibition in the FTMs. However, 
the TEWL of NHS was approximately 4.5 times lower than that of the 
FTMCONTROL. 
Fig. 3. SCD-1 inhibition led to a reduction in the amount of monounsaturated FFAs. (a) Amount of FFA in nMol/mg SC (b) Absolute saFFAs as function of chain 
length; (c) Absolute amount of muFFAs as function of chain length; (d) Absolute amount of muFFA in nmol/mg SC; (e) The percentage of muFFA; (f) the saFFA MCL. 
For statistical analysis, an unpaired t-test was performed between the FTMCONTROL and FTMSCD-1. To determine whether significant differences were observed be-
tween FTMCONTROL and NHS, an unpaired t-test was used. Significant differences are indicated by * for p < 0.05, ** for p < 0.01, and *** for p < 0.001. 
Fig. 4. Minor changes in the expression of genes involved in lipid synthesis, lipid processing, or CER synthesis after SCD-1 inhibition. Lipid synthesis genes 
investigated for FTMCONTROL, FTMSCD-1, and NHS. (a) Lipid synthesis genes SREBP-1c, ACC, and FAS. (b) Lipid elongases ELOVL-1 and ELOVL-4. (c) Lipid desaturase 
SCD-1 and LXR downstream target ABCA1. (d) CER synthases 2–6, and (e) CER processing enzymes DES1 and DES2. For statistical analysis, an unpaired t-test was 
performed between the FTMCONTROL and FTMSCD-1. To compare the FTMCONTROL and NHS, an unpaired t-test was used. Significant differences are indicated by * for p 
< 0.05, ** for p < 0.01. 
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4. Discussion 
Our aim was to improve the lipid composition and organization in 
the FTM model by modulating the activity of SCD-1. By inhibiting SCD- 
1, several modifications were observed on the lipid composition. The 
most important modification was the reduction in the amount of muC-
ERs and muFFAs in the SC of the FTMSCD-1, which resembles the lipid 
composition in NHS more closely. Another important finding was that 
the quantity of lipids remained similar after SCD-1 inhibition, which 
indicates that the total amount of lipids synthesized was unaffected by 
the SCD-1 inhibition and thus the synthesis of saCERs and saFFAs was 
increased at the expense of the monounsaturated variant. In addition, 
several other lipid compositional changes were observed. 
First, there was a strong decrease in the amount of CER[EO] 
observed in the FTMSCD-1. Interestingly, when displaying the individual 
CER[EO] subsets, both muCER[EO-18:2] and saCER[EO-18:1] are 
reduced, together with the main CER[EO] peak composed of two CER 
subclasses: muCER[EO-18:1]/saCER[EO-18:2]. This reveals that not 
only the muCER[EO] contributed to this reduction, but the CER[EO- 
18:1] as well. To understand why the CER[EO] was reduced, as a first 
possible underlying factor, enzymes responsible for the synthesis of CER 
[EO] were investigated. For this synthesis CerS3 and ELOVL4 are 
required [30], but the gene level for ELOVL4 and CerS3 did not change 
between FTMCONTROL and FTMSCD-1. A second possible factor is an in-
crease in CER[O], since CER[EO] is a precursor for CER[O] [31,32]. 
However, similar amounts of CER[O] were observed in the FTMs. A 
third explanation is a reduction in the amount of oleic acid (C18:1) for 
the synthesis of the CER[EO-18:1]. The amount of C18:1 was reduced in 
the FTMSCD-1 and therefore might be an underlying factor of the 
reduction of CER[EO-18:1]. When comparing FTMs to NHS, the amount 
of CER[EO] in FTMs is increased. Both CerS3 and ELOVL4 are known to 
play a key role in the synthesis of CER [4,30], the increased mRNA 
expression of these genes in FTMs might explain why the amount of CER 
[EO] is higher in FTMs. 
Second, we observed an increase in the absolute amount of CER[dS] 
in the FTMSCD-1 compared to the FTMCONTROL. This effect was even more 
prevalent when relative amounts of CERs were calculated. To investi-
gate whether the increase in the amount of CER[dS] was due to a 
reduction in the CER head group synthesis genes, the CER subclass 
synthases DES1 and DES2 that are responsible for the conversion of CER 
[dS] to CER[S] and CER[P], respectively, were investigated on gene 
level. As both FTMs had similar mRNA level for DES1 and DES2, there is 
no indication that these genes are an underlying factor of the shift to-
wards more CER[dS]. However, when observing the morphology of the 
FTMSCD-1, the epidermis does appear thinner. Perhaps, the 
differentiation is performed more rapidly, giving the ceramide pro-
cessing enzymes less time to convert the head groups resulting in a 
higher level of CER[dS]. In addition, higher levels of CER[dS] were also 
observed in mouse skin, which also has a very thin epidermis [33]. 
Indicating that the thickness of the epidermis might have an impact on 
the subclasses. 
When studying epidermal morphology and protein expression, an 
interesting observation is that SCD-1 inhibition resulted in a drastic 
increase in SCD-1 expression on both protein and RNA level. Even with 
an increased expression, the SCD-1 inhibitor still inhibited the majority 
of the protein, since there was a significant reduction in muCERs 
observed. This increase in SCD-1 protein level was likely due to the 
necessity to maintain several crucial biological processes, such as 
regulating cell survival, membrane integrity, or preventing lipotoxity in 
the cells [34–38]. 
Although the effects of SCD-1 inhibiting resulted in an improved 
lipid composition, the observed changes ultimately did not lead to al-
terations in the lateral organization and both FTMs adopted a hexagonal 
lipid organization. In order to advance the lipid organization of FTMs, 
several key-changes may be an important next step to generate FTMs 
with normalized barrier function: 1) Perhaps the most crucial change, is 
the increase in the quantity of FFAs. In NHS, the ratio between CER:FFA 
in this study is approximately 0.8:1, whereas the ratio in FTMs is 
approximately 1:0.125. Normalization of this ratio would promote the 
lipids to adopt an orthorhombic packing in FTMs [39]. 2) An increase in 
the MCL of both CERs and FFAs would enhance SC lipids to adopt an 
orthorhombic organization [21]. Another study demonstrated that LXR 
inhibition reduced the muCERs, but at the same time also an increase in 
chain length was observed [21]. This subsequently also led to an 
improved lipid organization, demonstrating the importance of targeting 
both the monounsaturation and lipid chain length. 3) A further reduc-
tion in the amount of muCERs and muFFAs would likely result in a 
higher fraction of lipids forming an orthorhombic organization as shown 
in previous studies [9]. 
SCD-1 inhibition did not alter the lamellar organization. The 
diffraction patterns of the FTMs revealed lamellar phases in the FTMs. 
Although it remains to be elucidated why the phases + and # formed, 
these small changes are most probably observed due to the CER subclass 
composition as this composition is crucial for the formation of the 
lamellar phases [40]. In the FTMSCD-1, the fraction of CER[EO] is 
reduced and the additional phase + is no longer present, which could 
indicate that the abundant presence of CER[EO] contributes to this peak 
as suggested in previous studies [41]. The phase # might be attributed to 
the increased amounts of CER[dS] in the FTMSCD-1, since the FTMCON-
TROL does not contain this phase. 
Fig. 5. SCD-1 inhibition does not change lipid organizations or lipid permeation. The lipid organization was analyzed for the FTMs and NHS at 24 ◦C (a) the lateral 
organization by displaying the rocking region and (b) X-ray diffraction profile for FTMs and the LPP repeat distance. Diffraction order of the LPP is indicated by I, II, 
and III. The cholesterol phase is indicated by the asterix (*). Unknown phases are indicated by + and #. The repeat distance is provided in the bar plot, with NHS as a 
reference [18]. (c) The TEWL values are plotted in a barplot. For statistical analysis, an unpaired t-test was performed between the FTMCONTROL and FTMSCD-1. After, 
to compare the FTMCONTROL vs NHS, an unpaired t-test was used. Significant differences are indicated by *** for p < 0.001. 
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To conclude, this study demonstrates that SCD-1 activity could be 
successfully reduced and that SCD-1 modulation can be a tool to lower 
the amount of muCERs and muFFAs in our FTM models. However, 
although a reduced SCD-1 activity improved the lipid composition, it did 
not result in an improved barrier function. This demonstrates the 
complexity of the lipid synthesis and the subsequent formation of the 
lipid organization. Nevertheless, it is important to know that the 
approach to reduce the monounsaturated lipids is useful, it should be 
combined with other targeted approaches to improve the lipid compo-
sition in order to generate the next generation of FTMs that even better 
mimic NHS. 
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[6] M. Schäfer-Korting, et al., Reconstructed human epidermis for skin absorption 
testing: results of the German prevalidation study, Altern. Lab. Anim 34 (2006) 
283–294. 
[7] M. , V.G., et al., Three-dimensional skin models as tools for transdermal drug 
delivery: challenges and limitations. Expert Opin Drug Deliv., 2011 8(6): p. 
705–20. 
[8] G.E. Flaten, et al., In vitro skin models as a tool in optimization of drug 
formulation, Eur. J. Pharm. Sci. 30 (75) (2015) 10–24. 
[9] E.H. Mojumdar, et al., Monounsaturated fatty acids reduce the barrier of stratum 
corneum lipid membranes by enhancing the formation of a hexagonal lateral 
packing, Langmuir. 30 (22) (2014) 6534–6543. 
[10] J. van Smeden, et al., The importance of free fatty acid chain length for the skin 
barrier function in atopic eczema patients, Exp. Dermatol. 23 (1) (2014) 45–52. 
[11] J., V.S. and J.A. Bouwstra, Stratum corneum lipids: their role for the skin barrier 
function in healthy subjects and atopic dermatitis patients. Curr Probl Dermatol., 
2016. 49: p. 8–26. 
[12] E. Proksch, J.M. Brandner, J.M. Jensen, The skin: an indispensable barrier, Exp. 
Dermatol. 17 (12) (2008) 1063–1072. 
[13] S. Motta, et al., Ceramide composition of the psoriatic scale, Biochim. Biophys. 
Acta 1182 (2) (1993) 147–151. 
[14] W. Boiten, et al., Quantitative analysis of ceramides using a novel lipidomics 
approach with three dimensional response modelling, Biochimica et Biophysica 
Acta (BBA) - Molecular and Cell Biology of Lipids 1861 (11) (2016) 1652–1661. 
[15] R. t’Kindt, et al., Profiling and characterizing skin ceramides using reversed-phase 
liquid chromatography–quadrupole time-of-flight mass spectrometry, Anal. Chem. 
84 (1) (2012) 403–411. 
[16] V.S. Thakoersing, et al., Increased presence of monounsaturated fatty acids in the 
stratum corneum of human skin equivalents, J. Investig. Dermatol. 133 (1) (2013) 
59–67. 
[17] J. van Smeden, et al., LC/MS analysis of stratum corneum lipids: ceramide profiling 
and discovery, J. Lipid Res. 52 (6) (2011) 1211–1221. 
[18] J.A. Bouwstra, et al., Structural investigations of human stratum corneum by small- 
angle X-ray scattering, J Invest Dermatol (6) (1991) 1005–1012. 
[19] M. Boncheva, The physical chemistry of the stratum corneum lipids, Int. J. Cosmet. 
Sci. 36 (6) (2014) 505–515. 
[20] V.S. Thakoersing, et al., Unraveling barrier properties of three different in-house 
human skin equivalents, Tissue Engineering Part C: Methods 18 (1) (2011) 1–11. 
[21] R.W.J. Helder, et al., The effects of LXR agonist T0901317 and LXR antagonist 
GSK2033 on morphogenesis and lipid properties in full thickness skin models, 
Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1865 (2019). 
[22] C.M. Paton, J.M. Ntambi, Biochemical and physiological function of stearoyl-CoA 
desaturase, Am. J. Physiol. Endocrinol. Metab. 297 (1) (2009) E28–E37. 
[23] M. Rabionet, K. Gorgas, R. Sandhoff, Ceramide synthesis in the epidermis, Biochim. 
Biophys. Acta 1841 (3) (2014) 422–434. 
[24] A. Kihara, Synthesis and degradation pathways, functions, and pathology of 
ceramides and epidermal acylceramides, Prog. Lipid Res. 63 (2016) 50–69. 
[25] Y. Mizutani, et al., Ceramide biosynthesis in keratinocyte and its role in skin 
function, Biochimie 91 (2009) 784–790. 
[26] Y. Masukawa, et al., Comprehensive quantification of ceramide species in human 
stratum corneum, J. Lipid Res. 50 (8) (2009) 1708–1719. 
[27] V. van Drongelen, et al., Barrier properties of an N/TERT-based human skin 
equivalent, Tissue Eng Part A. 20 (21− 22) (2014) 3041–3049. 
[28] M. Ponec, et al., The formation of competent barrier lipids in reconstructed human 
epidermis requires the presence of vitamin C, J Invest Dermatol. 109 (3) (1997) 
348–355. 
[29] Helder, R.W.J., et al., Contribution of palmitic acid to epidermal morphogenesis 
and lipid barrier formation in human skin equivalents. Int J Mol Sci., 2019. 20(23). 
[30] Y. Mizutani, et al., Cooperative synthesis of ultra long-chain fatty acid and 
ceramide during keratinocyte differentiation, PLoS One 8 (2013). 
[31] Y. Zheng, et al., Lipoxygenases mediate the effect of essential fatty acid in skin 
barrier formation: a proposed role in releasing omega-hydroxyceramide for 
construction of the corneocyte lipid envelope, J. Biol. Chem. 286 (27) (2011) 
24046–24056. 
[32] P. Krieg, G. Fürstenberger, The role of lipoxygenases in epidermis, Biochim. 
Biophys. Acta 1841 (2014) 390–400. 
[33] R. Martins Cardoso, et al., Barrier lipid composition and response to plasma lipids: 
a direct comparison of mouse dorsal back and ear skin, Exp Dermatol (2020) 
548–555. 
[34] M. Miyazaki, W.C. Man, J.M. Ntambi, Targeted disruption of stearoyl-CoA 
desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and 
depletion of wax esters in the eyelid, J. Nutr. 131 (2001) 2260–2268. 
[35] S. Jackowski, Cell cycle regulation of membrane phospholipid metabolism, J. Biol. 
Chem. 1271 (1996) 20219–20222. 
[36] H. Sampath, et al., Skin-specific deletion of stearoyl-CoA desaturase-1 alters skin 
lipid composition and protects mice from high fat diet-induced obesity, J. Biol. 
Chem. 284 (30) (2009) 19961–19973. 
[37] L.S. Golfman, M. Bakovic, D.E. Vance, Transcription of the CTP: phosphocholine 
cytidylyltransferase alpha gene is enhanced during the S phase of the cell cycle, 
J. Biol. Chem. 276 (2001) 43688–43692. 
[38] L.O. Li, E.L. Klett, R.A. Coleman, Acyl-CoA synthesis, lipid metabolism and 
lipotoxicity, Biochim. Biophys. Acta 1801 (2010) 246–251. 
[39] J.A. Bouwstra, et al., Phase behavior of lipid mixtures based on human ceramides: 
coexistence of crystalline and liquid phases, J. Lipid Res. 42 (2001) 1759–1770. 
[40] J.v. Smeden, et al., The important role of stratum corneum lipids for the cutaneous 
barrier function, Biochim Biophys Acta 1841 (2014) 295–313. 
[41] D. Groen, G.S. Gooris, J.A. Bouwstra, Model membranes prepared with ceramide 
EOS, cholesterol and free fatty acids form a very unique lamellar phase, Langmuir 
26 (2010) 4168–4175. 
R.W.J. Helder et al.                                                                                                                                                                                                                            
